RxDoctor Payments Data

Richard Sarle, MD

Urology · Battle Creek, MINPI 1558310920

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Bayer at 31.3% of the total. Among urology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,811in general payments, 2019–2025

Across 364 payments — averaging $90.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$10K
  • Johnson & Johnson$3K
  • Myovant Sciences Inc.$3K
  • Astellas Pharma US Inc$2K
  • AstraZeneca$2K
  • Procept Biorobotics Corporation$2K
  • plus $10K from 52 others

What the payments were for

  • Consulting fees$16,33650%
  • Speaking & faculty fees$2,9509%
  • Travel & lodging$2,5878%
  • Food & beverage$10,45632%
  • Education$4821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer20$10,279
Johnson & Johnson(3 entities)30$3,324
Myovant Sciences Inc.7$2,809
Astellas Pharma US Inc16$2,407
AstraZeneca7$2,096
Procept Biorobotics Corporation14$1,625
Janssen Scientific Affairs, LLC10$1,479
Intuitive Surgical6$1,027
Pfizer22$773
Boston Scientific13$590
Sumitomo Pharma America, Inc.28$580
Olympus America Inc.10$424
Medtronic(2 entities)10$412
Dendreon Pharmaceuticals LLC17$410
Urogen Pharma, Inc.9$406
Myriad Genetic Laboratories, Inc.22$378
Ferring Pharmaceuticals Inc.9$278
Laborie Medical Technologies Corp.2$237
Teleflex LLC2$233
Coloplast9$217
Dornier Medtech America, Inc1$213
Progenics Pharmaceuticals, Inc.5$196
Photocure Inc5$167
Axonics, Inc.5$159
Blue Earth Diagnostics7$152
Calyxo, Inc.1$150
Immunitybio, Inc.3$137
Histosonics, Inc.1$133
Antares Pharma, Inc.7$122
Tolmar, Inc.7$122
AbbVie(2 entities)7$116
Heron Therapeutics, Inc.1$98
C. R. Bard, Inc. & Subsidiaries4$91
Amgen5$89
Neotract Inc.1$86
Merck4$73
Sun Pharmaceutical Industries Inc.2$67
Cook Medical LLC2$53
Telix Pharmaceuticals2$52
Travere Therapeutics, Inc.5$47
Cycle Pharmaceuticals Inc2$46
KARL Storz Endoscopy-america1$45
Halozyme Inc2$44
Endo Pharmaceuticals Inc.3$41
Foundation Medicine, Inc.1$39
Novartis2$38
Clarus Therapeutics Inc.2$35
Urovant Sciences Inc2$33
Tolmar Pharmaceuticals, Inc.2$27
Alnylam Pharmaceuticals Inc.1$24
Acerus Pharmaceuticals Corporation1$22
Metuchen Pharmaceuticals1$18
Koelis Inc.1$16
Avadel Specialty Pharmaceuticals, LLC1$16
Smith+Nephew1$16
Dentsply IH Inc.1$14
Endo USA, Inc.1$14
E.r. Squibb & Sons, L.L.C.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,811 in reported general payments places this provider in the 90th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$97,401
Medicare patients
353
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix48$127,600
GemtesaVibegron53$53,705
MyrbetriqMirabegron57$39,718
Dutasteride284$13,899
Mirabegron ErMirabegron18$11,019
Tamsulosin Hcl551$10,361
Alfuzosin Hcl ErAlfuzosin Hcl83$2,432
Silodosin18$2,077
Solifenacin Succinate38$1,755
Finasteride50$768
Tadalafil19$691
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$198
Levofloxacin115$193
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$580$181,305101 claims
Astellas Pharma US IncMyrbetriq$2,407$39,71857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 urology providers in Michigan.

Other urology in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →